Page 85 - OR-1-1

109. Hubert CG, Rivera M, Spangler LC, et al. A three- Neurosci. 2018;21(10):1332-1340.
dimensional organoid culture system derived from human doi: 10.1038/s41593-018-0235-9
glioblastomas recapitulates the hypoxic gradients and cancer
stem cell heterogeneity of tumors found in vivo. Cancer Res. 121. Wray S. Modelling neurodegenerative disease using brain
2016;76(8):2465-2477. organoids. Semin Cell Dev Biol. 2021;111:60-66.
doi: 10.1158/0008-5472.CAN-15-2402 doi: 10.1016/j.semcdb.2020.05.012

110. Jacob F, Salinas RD, Zhang DY, et al. A patient-derived 122. Van Vliet EF, Knol MJ, Schiffelers RM, Caiazzo M, Fens
glioblastoma organoid model and biobank recapitulates MHAM. Levodopa-loaded nanoparticles for the treatment
inter- and intra-tumoral heterogeneity. Cell. 2020;180(1):188- of Parkinson’s disease. J Control Release. 2023;360:212-224.
204.e22. doi: 10.1016/j.jconrel.2023.06.026
doi: 10.1016/j.cell.2019.11.036 123. Tagliaferro P, Burke RE. Retrograde axonal degeneration in
111. Lu P, Weaver VM, Werb Z. The extracellular matrix: Parkinson disease. J Parkinsons Dis. 2016;6(1):1-15.
A dynamic niche in cancer progression. J Cell Biol. doi: 10.3233/JPD-150769
2012;196(4):395-406.
124. Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics
doi: 10.1083/jcb.201102147 and pathogenesis of Parkinson’s syndrome. Annu Rev Pathol.
112. Quail DF, Joyce JA. The microenvironmental landscape of 2023;18:95-121.
brain tumors. Cancer Cell. 2017;31(3):326-341. doi: 10.1146/annurev-pathmechdis-031521-034145
doi: 10.1016/j.ccell.2017.02.009 125. Burbulla LF, Song P, Mazzulli JR, et al. Dopamine oxidation
113. Linkous A, Balamatsias D, Snuderl M, et al. Modeling mediates mitochondrial and lysosomal dysfunction in
patient-derived glioblastoma with cerebral organoids. Cell Parkinson’s disease. Science. 2017;357(6357):1255-1261.
Rep. 2019;26(12):3203-3211.e5. doi: 10.1126/science.aam9080
doi: 10.1016/j.celrep.2019.02.063 126. Bartels T, De Schepper S, Hong S. Microglia modulate
114. Weth FR, Peng L, Paterson E, Tan ST, Gray C. Utility of neurodegeneration in Alzheimer’s and Parkinson’s diseases.
the cerebral organoid glioma ‘GLICO’ model for screening Science. 2020;370(6512):66-69.
applications. Cells. 2022;12(1):153. doi: 10.1126/science.abb8587
doi: 10.3390/cells12010153 127. Lan G, Wang P, Chan RB, et al. Astrocytic VEGFA: An
115. Louis DN, Perry A, Reifenberger G, et al. The 2016 World essential mediator in blood-brain-barrier disruption in
Health Organization classification of tumors of the Parkinson’s disease. Glia. 2022;70(2):337-353.
central nervous system: A summary. Acta Neuropathol. doi: 10.1002/glia.24109
2016;131(6):803-820.
128. Kam TI, Hinkle JT, Dawson TM, Dawson VL. Microglia and
doi: 10.1007/s00401-016-1545-1 astrocyte dysfunction in Parkinson’s disease. Neurobiol Dis.
116. Zhang C, Jin M, Zhao J, Chen J, Jin W. Organoid models of 2020;144:105028.
glioblastoma: Advances, applications and challenges. Am J doi: 10.1016/j.nbd.2020.105028
Cancer Res. 2020;10(8):2242-2257.
129. Isik S, Yeman Kiyak B, Akbayir R, Seyhali R, Arpaci T.
117. Bian S, Repic M, Guo Z, et al. Genetically engineered cerebral Microglia Mediated neuroinflammation in Parkinson’s
organoids model brain tumor formation. Nat Methods. disease. Cells. 2023;12(7):1012.
2018;15(8):631-639.
doi: 10.3390/cells12071012
doi: 10.1038/s41592-018-0070-7
130. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH.
118. Ogawa J, Pao GM, Shokhirev MN, Verma IM. The pathogenesis of Parkinson’s disease. Lancet.
Glioblastoma model using human cerebral organoids. Cell 2024;403(10423):293-304.
Rep. 2018;23(4):1220-1229.
doi: 10.1016/S0140-6736(23)01478-2
doi: 10.1016/j.celrep.2018.03.105
131. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification
119. Zhang L, Liu F, Weygant N, et al. A novel integrated system of novel risk loci, causal insights, and heritable risk for
using patient-derived glioma cerebral organoids and Parkinson’s disease: A meta-analysis of genome-wide
xenografts for disease modeling and drug screening. Cancer association studies. Lancet Neurol. 2019;18(12):1091-1102.
Lett. 2021;500:87-97.
doi: 10.1016/S1474-4422(19)30320-5
doi: 10.1016/j.canlet.2020.12.013
132. Pan H, Liu Z, Ma J, et al. Genome-wide association study
120. Soto C, Pritzkow S. Protein misfolding, aggregation, and using whole-genome sequencing identifies risk loci for
conformational strains in neurodegenerative diseases. Nat Parkinson’s disease in Chinese population. NPJ Parkinsons

Volume 1 Issue 1 (2025) 19 doi: 10.36922/or.8261